Tempus AI (NASDAQ:TEM) CEO Sells 22,335 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 22,335 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $984,303.45. Following the completion of the sale, the chief executive officer directly owned 2,230,721 shares in the company, valued at approximately $98,307,874.47. The trade was a 0.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Trading Up 1.3%

NASDAQ:TEM traded up $0.61 during trading hours on Thursday, reaching $46.49. 3,802,434 shares of the stock were exchanged, compared to its average volume of 5,629,236. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32. The business has a 50-day moving average of $49.11 and a two-hundred day moving average of $59.69. The company has a market capitalization of $8.35 billion, a price-to-earnings ratio of -27.03 and a beta of 3.99. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. During the same period last year, the business posted ($0.24) EPS. Tempus AI’s revenue for the quarter was up 36.1% on a year-over-year basis. On average, equities analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

TEM has been the topic of several research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research report on Wednesday, March 11th. Guggenheim lowered their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. TD Cowen increased their price target on shares of Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Stifel Nicolaus set a $60.00 price objective on shares of Tempus AI in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $68.64.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently modified their holdings of the stock. GC Wealth Management RIA LLC purchased a new position in Tempus AI during the fourth quarter worth about $399,267,000. Vanguard Group Inc. boosted its holdings in Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Voloridge Investment Management LLC boosted its holdings in Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after purchasing an additional 1,039,176 shares in the last quarter. BNP Paribas Financial Markets increased its position in Tempus AI by 312.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after purchasing an additional 965,730 shares during the period. Finally, AQR Capital Management LLC acquired a new position in Tempus AI during the 2nd quarter worth approximately $54,020,000. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.